RxDoctor Payments Data

H Roger Rizi, MD

Cardiology · Long Beach, CANPI 1598795775

Payments from drug & device makers

$234in general payments, 2019–2025

Across 8 payments — averaging $29.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$119
  • Sanofi-aventis U.S. LLC$64
  • Regeneron Healthcare Solutions, Inc.$19
  • Kowa Pharmaceuticals America, Inc.$18
  • Johnson & Johnson$14

What the payments were for

  • Food & beverage$21592%
  • Education$198%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$234 in reported general payments places this provider in the 50th percentile of 156 cardiology providers in California.

See all cardiology providers in California

Medicare billing

Part B allowed, 2024
$423,574
Medicare patients
464
Services billed
3,040

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban190$248,973
EntrestoSacubitril/Valsartan206$230,689
Repatha SureclickEvolocumab150$151,771
XareltoRivaroxaban57$62,405
JardianceEmpagliflozin57$52,878
FarxigaDapagliflozin Propanediol23$31,853
Praluent PenAlirocumab38$26,628
OzempicSemaglutide12$14,000
Amlodipine-ValsartanAmlodipine Besylate/Valsartan209$12,257
Icosapent Ethyl40$11,867
Ezetimibe295$9,909
Rosuvastatin Calcium448$8,031
Valsartan209$6,947
Atorvastatin Calcium563$5,561
Nebivolol Hcl81$5,304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$14$62,40557 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 156 cardiology providers in California.

Other cardiology in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →